<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sinus tachycardia: Evaluation and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sinus tachycardia: Evaluation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sinus tachycardia: Evaluation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Munther K Homoud, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Piccini, MD, MHS, FACC, FAHA, FHRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sinus tachycardia is a rhythm in which the rate of impulses arising from the sinoatrial (SA) node is elevated. Sinus tachycardia is most often a normal and physiologic response, for example during exercise. However, sinus tachycardia can in some instances be inappropriate or pathologic. It is one of the most commonly encountered (and often overlooked) heart rhythms that may portend an adverse prognosis, particularly in patients with cardiovascular disease.</p><p>The etiology, clinical presentation, evaluation, and management of sinus tachycardia, including inappropriate sinus tachycardia, will be reviewed here. Other supraventricular tachycardias, including sinoatrial reentry supraventricular tachycardia (which involves tissue from the SA node), are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/936.html" rel="external">"Overview of the acute management of tachyarrhythmias", section on 'Narrow QRS complex tachyarrhythmias'</a> and  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a>.)</p><p class="headingAnchor" id="H615690343"><span class="h1">DEFINITION AND ECG FEATURES</span><span class="headingEndMark"> — </span>Normal sinus rhythm (NSR) is the characteristic rhythm of the healthy human heart. NSR is considered to be present in adults if the heart rate is between 60 and 100 beats per minute, the P wave vector on the electrocardiogram (ECG) is normal, and the rate is largely regular  (<a class="graphic graphic_waveform graphicRef58149" href="/d/graphic/58149.html" rel="external">waveform 1</a>). Inspection of the P-wave vector is often overlooked but is important. The normal sinus P wave demonstrates right followed by left atrial depolarization giving rise to an upright P wave in leads I, II and aVL, and a negative P wave in lead aVR.</p><p>By conventional definition, a tachycardia requires the heart rate to be greater than 100 beats per minute. As such, sinus tachycardia can be thought of as a sinus-driven rhythm (normal-appearing P wave axis on the surface ECG) which is occurring at a rate of greater than 100 beats per minute  (<a class="graphic graphic_waveform graphicRef78938" href="/d/graphic/78938.html" rel="external">waveform 2</a>).</p><p>However, the "normal" heart rate is, in part, the result of the complex interplay between the sympathetic and parasympathetic nervous systems. It is affected by numerous factors and varies in part with age  (<a class="graphic graphic_table graphicRef77746" href="/d/graphic/77746.html" rel="external">table 1</a>) [<a href="#rid1">1-3</a>]. The heart rate is usually between 110 and 150 beats per minute in infants, with gradual slowing over the next six years. The resting sinus rate in older children and adults is approximately 65 to 85 beats per minute, with slowing in older age [<a href="#rid4">4-6</a>]. There is also considerable variation based upon level of fitness and underlying medical comorbidities. (See  <a class="medical medical_review" href="/d/html/1073.html" rel="external">"Normal sinus rhythm and sinus arrhythmia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ETIOLOGY AND CLINICAL SYNDROMES</span></p><p class="headingAnchor" id="H2014638883"><span class="h2">Sinus tachycardia as a physiologic response</span><span class="headingEndMark"> — </span>In the majority of patients, sinus tachycardia is a physiologic response to a demand for greater cardiac output, increased sympathomimetic state, or vagal/parasympathetic withdrawal. Sinus tachycardia is an important mechanism for increasing cardiac output in the setting of infection or volume depletion or other stressors/illnesses.</p><p>Sinus tachycardia is a normal physiologic response to exercise and conditions in which catecholamine release is physiologically enhanced or, less commonly, in situations where the parasympathetic nervous system is withdrawn. A long list of other factors may be responsible in selected cases, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever</p><p class="bulletIndent1"><span class="glyph">●</span>Volume depletion</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension and shock</p><p class="bulletIndent1"><span class="glyph">●</span>Sepsis</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxia</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism</p><p class="bulletIndent1"><span class="glyph">●</span>Acute coronary ischemia and myocardial infarction</p><p class="bulletIndent1"><span class="glyph">●</span>Pain</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety</p><p class="bulletIndent1"><span class="glyph">●</span>Sleep deprivation</p><p class="bulletIndent1"><span class="glyph">●</span>Pheochromocytoma</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism</p><p class="bulletIndent1"><span class="glyph">●</span>Decompensated heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic pulmonary disease</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to stimulants (nicotine, caffeine, amphetamines), anticholinergic drugs, beta blocker withdrawal, or illicit drugs</p><p class="bulletIndent1"><span class="glyph">●</span>Abrupt withdrawal of medications such as beta blockers</p><p></p><p class="headingAnchor" id="H1388919111"><span class="h2">Postural orthostatic tachycardia syndrome</span><span class="headingEndMark"> — </span>Postural orthostatic tachycardia syndrome (POTS) is a condition that occurs predominantly in young women in the absence of structural heart disease. Characteristically, patients develop symptoms upon assuming the standing position. Symptoms may include palpitations, fatigue, lightheadedness, or exercise intolerance. The 2015 Heart Rhythm Consensus statement defined POTS as a heart rate rise of ≥30 beats per minute (≥40 beats per minute in individuals 12 to 19 years of age) in the absence of orthostatic hypotension (≥20 mmHg systolic blood pressure drop) [<a href="#rid7">7</a>]. Sinus tachycardia is only one component of this condition, which is a disorder of autonomic dysregulation [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/5100.html" rel="external">"Postural tachycardia syndrome"</a>.)</p><p class="headingAnchor" id="H57912739"><span class="h2">Inappropriate sinus tachycardia</span><span class="headingEndMark"> — </span>Inappropriate sinus tachycardia, also called chronic nonparoxysmal sinus tachycardia, is an unusual condition that occurs in individuals without apparent heart disease or other cause for sinus tachycardia, such as hyperthyroidism or fever, and is generally considered a diagnosis of exclusion [<a href="#rid9">9-12</a>]. Inappropriate sinus tachycardia is defined as a resting heart rate &gt;100 beats per minute (with a mean heart rate &gt;90 beats per minute over 24 hours) associated with highly symptomatic palpitations [<a href="#rid7">7,13</a>]. Commonly used criteria to define inappropriate sinus tachycardia include [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>P wave axis and morphology similar or identical to sinus rhythm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resting heart rate of 100 beats per minute or greater (with a mean heart rate &gt;90 beats per minute over 24 hours) or with activity heart rates of 100 beats per minute or greater but in excess of what one would expect for the amount of exertion. Additionally, patients with inappropriate sinus tachycardia classically experience a drop in heart rate during sleep.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations, presyncope, or both related to the tachycardia. Very rarely do patients experience syncope.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of identifiable causes of sinus tachycardia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exclusion of atrial tachycardia.</p><p></p><p>Most of these patients are young and female. Among a single-center cohort of 305 patients with inappropriate sinus tachycardia seen between 1998 and 2018, 92 percent were female, with an average age of 33 years [<a href="#rid15">15</a>]. Affected patients have an elevated resting heart rate and/or an exaggerated heart rate response to exercise that is out of proportion to the body's physiological needs; many patients have both.</p><p>Patients are invariably symptomatic; the presence of symptoms is an essential component of the definition. In contrast to sinus tachycardia occurring as a physiologic response, inappropriate sinus tachycardia can continue for months or years and may produce troublesome symptoms, most commonly with palpitations, but other common symptoms include chest discomfort, fatigue, dizziness/presyncope/syncope, and shortness of breath [<a href="#rid15">15</a>]. Most patients have resting heart rates of greater than 100 beats per minute and average heart rates on a 24-hour Holter greater than 90 beats per minute with no clear physiologic, pathologic, or pharmacologic trigger [<a href="#rid12">12</a>]. Characteristic of this disorder, the mean heart rate drops during sleep. Absence of nocturnal abatement of tachycardia should prompt consideration of a diagnosis other than inappropriate sinus tachycardia. The diurnal variations in heart rate seen in inappropriate sinus tachycardia may explain the low incidence of developing tachycardia-associated cardiomyopathy in this disease [<a href="#rid12">12,16</a>]. However, patients may rarely develop cardiomyopathy secondary to a sustained rapid heart rate. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p>The pathophysiologic mechanism behind this disease is poorly understood and is thought to consist of intrinsic sinus node hyperactivity coupled with autonomic perturbations modulated by neurohormonal influences [<a href="#rid12">12</a>]. One study suggested that this tachycardia is related to a primary sinus node abnormality, characterized by a high intrinsic heart rate, depressed efferent cardiovagal reflex, and beta-adrenergic hypersensitivity [<a href="#rid10">10,17</a>]. Both <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> and enhanced vagal tone shift the pacemaker site along the crista terminalis, while <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a> slows the rate but has little effect on the pacemaker focus and on activation sequence [<a href="#rid18">18,19</a>]. The shifting site of the SA pacemaker within the large epicardial SA nodal complex can be problematic when ablation is considered as a therapy [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H705920501"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most patients with physiologic sinus tachycardia do not have symptoms directly attributable to the tachycardia itself but present with signs or symptoms related to the associated condition (eg, pain, fever, shortness of breath, etc). However, a patient with a greater awareness of his or her heartbeat may report palpitations (subjective awareness of a rapid or forceful heartbeat).</p><p>In contrast, patients with postural orthostatic tachycardia syndrome or inappropriate sinus tachycardia are commonly symptomatic, as discussed above. (See <a class="local">'Postural orthostatic tachycardia syndrome'</a> above and <a class="local">'Inappropriate sinus tachycardia'</a> above.)</p><p>As with any tachycardia, sinus tachycardia can indirectly lead to symptoms due to the impact of the tachycardia in the presence of underlying heart disease. Tachycardia may result in:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased cardiac output due to shortened ventricular filling time</p><p class="bulletIndent1"><span class="glyph">●</span>Increased myocardial oxygen consumption</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced coronary blood flow</p><p></p><p>The above physiologic changes induced by tachycardia may result in symptoms of angina or dyspnea, the severity of which will depend upon how rapidly the heart is beating and the extent of the underlying cardiac comorbidities. In rare cases, sustained inappropriate sinus tachycardia can lead to tachycardia-induced cardiomyopathy [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p>Examination of precordial pulsation and the arterial pulse as means of assessing heart rate and rhythm is discussed separately. (See  <a class="medical medical_review" href="/d/html/1081.html" rel="external">"Examination of the precordial pulsation"</a> and  <a class="medical medical_review" href="/d/html/1077.html" rel="external">"Examination of the arterial pulse"</a>.)</p><p class="headingAnchor" id="H705920510"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H5"><span class="h2">Confirm sinus tachycardia</span><span class="headingEndMark"> — </span>Sinus tachycardia is generally confirmed by ECG after a rapid pulse is identified on physical examination, with the diagnosis usually being easy to establish from the surface ECG. An upright P wave in leads I and II indicates a sinus origin of the tachycardia [<a href="#rid1">1</a>]. However, the P waves may be difficult to identify at heart rates above 140 beats per minute, since they are often superimposed on the preceding T wave  (<a class="graphic graphic_waveform graphicRef78938" href="/d/graphic/78938.html" rel="external">waveform 2</a>). As a result, sinus tachycardia can be confused with another supraventricular tachycardia.</p><p>Vagal maneuvers (eg, carotid sinus massage, Valsalva maneuver) or intravenous AV nodal blocking agents (eg, <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) may help in the differentiation of sinus tachycardia from another supraventricular tachycardia by inducing one or more of the following (see  <a class="medical medical_review" href="/d/html/1034.html" rel="external">"Vagal maneuvers"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Slowing the sinus rate to allow definitive identification of the sinus P waves.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Causing transient AV nodal block to make atrial flutter with 2:1 block  (<a class="graphic graphic_waveform graphicRef76876" href="/d/graphic/76876.html" rel="external">waveform 3</a>) or atrial tachycardia apparent.</p><p></p><p>Termination of a paroxysmal supraventricular tachycardia (atrioventricular nodal reentrant tachycardia or atrioventricular reentrant tachycardia). (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p class="headingAnchor" id="H3066436859"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Sinus tachycardia should be distinguished from atrial tachycardias, which may appear similar on the ECG. Focal atrial tachycardia is a regular atrial rhythm at a constant rate of &gt;100 beats per minute originating outside of the sinus node. If the focus of the atrial tachycardia is close to the sinoatrial (SA) node, such as in the case of atrial tachycardia emanating from the superior crista terminalis, the P wave may be similar in appearance to a sinus P wave, giving the impression of a sinus tachycardia. The sudden and inappropriate onset of tachycardia on an ECG monitor can help differentiate one from the other.</p><p>Sinus tachycardia also must be distinguished from sinoatrial nodal reentrant tachycardia. Sinus node reentrant tachycardia is a reentrant arrhythmia that is paroxysmal with a discrete onset and offset (unlike sinus tachycardia) [<a href="#rid1">1</a>]. Distinguishing focal atrial tachycardia or sinoatrial nodal reentrant tachycardia from sinus tachycardia can often only be accomplished in the EP laboratory. (See  <a class="medical medical_review" href="/d/html/900.html" rel="external">"Focal atrial tachycardia"</a> and  <a class="medical medical_review" href="/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a>.)</p><p>The primary distinction between sinus tachycardia and an atrial tachycardia is made based on the clinical situation and the onset and termination of the tachycardia. Sinus tachycardia is an appropriate response to a physiologic, pathologic, or pharmacologic trigger. Its onset and resolution are gradual. In contrast, atrial tachycardias are paroxysmal in nature with abrupt onset and termination. Atrial tachycardias can generally be distinguished by their abrupt onset and termination, in contrast to the slow ramping up and slowing down of the heart rate in sinus tachycardia [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H86518705"><span class="h2">Further evaluation</span><span class="headingEndMark"> — </span>For the majority of patients with sinus tachycardia, the underlying cause is determined from history and physical examination. Important features to elicit in a history and examination include exposure to stimulants and drugs, pain, and anxiety; and measurement of a full set of vital signs, including temperature and pulse oximetry [<a href="#rid13">13</a>].</p><p>Clues derived from the history and physical examination will direct subsequent evaluation, which can range from simple reassurance to admission and extensive testing depending on the situation. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pain or anxiety will often require only simple reassurance, with return of the sinus rate to the normal range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a fever or other signs of infection should have a complete blood count drawn along with workup focused at the source of infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with signs or symptoms of volume depletion should be rehydrated; if the suspected cause of the volume depletion is anemia, a complete blood count should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with signs of symptoms of hyperthyroidism (TSH), pheochromocytoma (24-hour urinary catecholamines and metanephrines), or another systemic illness should have an evaluation focused on the suspected disorder.</p><p></p><p>The most important component of evaluation in sinus tachycardia is determining if the sinus tachycardia is due to a physiologic insult such as infection, pulmonary embolus, or blood loss. Patients with sinus tachycardia who have hypotension or signs of shock related to suspected volume depletion, signs of sepsis related to infection, or acute clinical deterioration related to another suspected medical condition (eg, hypoxia, myocardial ischemia, heart failure, etc) should be admitted for evaluation and treatment.</p><p>The postural orthostatic tachycardia syndrome, of which sinus tachycardia is one component, is diagnosed using a set of diagnostic criteria that incorporates exaggerated postural changes in heart rate elicited by standing, in the absence of orthostatic hypotension. The diagnosis of inappropriate sinus tachycardia is challenging and is typically made in a patient with persistent tachycardia in whom other clinical entities have been excluded. (See <a class="local">'Inappropriate sinus tachycardia'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3341110807"><span class="h2">Treat the underlying cause</span><span class="headingEndMark"> — </span>In most settings, sinus tachycardia will improve or resolve following treatment directed at the underlying etiology. Rarely, patients with sinus tachycardia who have hypotension or signs of shock related to suspected volume depletion, signs of sepsis related to infection, or acute clinical deterioration related to another suspected medical condition (eg, hypoxia, myocardial ischemia, heart failure, etc) should be admitted for evaluation and treatment. Management is generally driven by the underlying causation, as therapy that is indicated for sinus tachycardia in certain conditions (eg, beta blockers for acute myocardial ischemia) may be contraindicated in other conditions (eg, hypovolemia or sepsis).</p><p class="headingAnchor" id="H9"><span class="h3">Management in patients with acute coronary syndrome</span><span class="headingEndMark"> — </span>Sinus tachycardia occurs in one-third or more of patients with acute coronary syndromes [<a href="#rid23">23,24</a>]. The reasons for sinus tachycardia in acute coronary syndromes can vary significantly from a reaction to pain, associated anxiety, hypoxia, or even impending cardiogenic shock.</p><p>The heart rate usually declines over time to a level that reflects the degree of activation of the sympathetic nervous system. Patients with persistent sinus tachycardia usually have larger infarcts that are more often anterior and a marked impairment in left ventricular function, which is associated with substantial morbidity and increased early and 30-day mortality [<a href="#rid24">24-27</a>]. In addition, sinus tachycardia may increase the size of ischemic injury and infarction due to increased myocardial oxygen demand.</p><p>In view of the prognostic importance of sinus tachycardia, it is important to exclude other causes of this arrhythmia. These include fear, anxiety, fever, pericarditis, and medications. Heart failure, hypoxia, recurrent ischemia, and hypotension should be aggressively treated. In the absence of identifiable triggers, sinus tachycardia in acute myocardial infarction can be treated with cautious beta blockade. However, most patients will receive such therapy independent of the tachycardia since early beta blocker administration is part of routine management of acute myocardial infarction. (See  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Inappropriate sinus tachycardia</span><span class="headingEndMark"> — </span>Treatment of symptomatic inappropriate sinus tachycardia is frequently challenging, often with suboptimal results [<a href="#rid7">7,13,28</a>]. Prior to beginning treatment, it is important to exclude other etiologies of sinus tachycardia, notably postural orthostatic tachycardia syndrome (POTS), and continue withdrawing any medications that may be contributing to tachycardia (eg, stimulants). (See <a class="local">'Catheter ablation'</a> below.)</p><p>The pharmacologic management of inappropriate sinus tachycardia continues to evolve as new treatments are being developed. Once other etiologies of sinus tachycardia have been excluded, our approach to therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptomatic inappropriate sinus tachycardia, we suggest a trial of beta blockade as the initial medical therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with persistently symptomatic inappropriate sinus tachycardia after a trial of beta blockers, we suggest using <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> (5 mg to 7.5 mg twice daily).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiofrequency catheter ablation to modify the sinus node may be a treatment of last resort for patients with refractory symptoms. However, symptomatic recurrence after sinus node modification is frequent, and repeated procedures often result in pacemaker implantation.</p><p></p><p class="headingAnchor" id="H708541358"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>While usually considered a first line of treatment, beta blockers have been poorly tolerated (usually due to the higher doses required for adequate heart rate control) and/or minimally effective for patients with inappropriate sinus tachycardia [<a href="#rid13">13,28</a>]. When attempting beta blocker therapy, we typically start long-acting <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> 50 mg daily, with upward titration for adequate heart rate and symptom control. The results with beta blockers are often disappointing, however, since even if ventricular rates can be controlled, the symptoms will often persist [<a href="#rid12">12,13</a>]. Beta blocker therapy may be effective if the cause of inappropriate sinus tachycardia is overactivity of the sympathetic nervous system [<a href="#rid29">29</a>]. However, control of the heart rate is difficult if the sinus tachycardia results from depressed vagal activity.</p><p class="headingAnchor" id="H2294345"><span class="h3">Ivabradine</span><span class="headingEndMark"> — </span>For patients with persistently symptomatic inappropriate sinus tachycardia, we suggest using <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> (5 mg to 7.5 mg twice daily) with or without a beta adrenergic receptor blocker. Although ivabradine is not available in all countries, and its use for inappropriate sinus tachycardia would be considered an off-label use in the United States, various professional society guidelines for the treatment of supraventricular tachycardia both support the use of ivabradine alone or, preferably, in conjunction with beta blockers for inappropriate sinus tachycardia [<a href="#rid7">7,13,28</a>].</p><p><a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">Ivabradine</a> is labeled by the FDA for use in patients with systolic heart failure (ejection fraction &lt;35 percent) with a resting heart rate above 70 beats per minute. It is a selective blocker of the sodium channel I<sub>f</sub>, one of the channels that regulates sinus node automaticity [<a href="#rid30">30-32</a>]. Ivabradine decreases the depolarizing I<sub>f</sub> current in the sinoatrial node, thereby decreasing the heart rate [<a href="#rid32">32,33</a>]. A large randomized study of ivabradine versus placebo in patients with coronary artery disease and left ventricular dysfunction supports the safety and efficacy of ivabradine for lowering heart rates, although these patients did not have inappropriate sinus tachycardia and there are limited data on long-term safety and efficacy [<a href="#rid34">34</a>]. Additionally, ivabradine appears to be an effective treatment option for patients with inappropriate sinus tachycardia [<a href="#rid35">35-38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and pooled analysis that included 145 patients (70 percent female) from nine studies (one randomized trial and eight observational studies), all studies reported a reduction in heart rate following <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> (averaging between 10 and 20 percent reduction in mean resting heart rate) [<a href="#rid39">39</a>]. The majority of patients also reported improvement in symptoms following ivabradine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a double-blind study of 21 patients with inappropriate sinus tachycardia, patients received either <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> (5 mg twice daily) or placebo for six weeks, followed by a washout period and cross over to the other treatment for six additional weeks [<a href="#rid36">36</a>]. Symptom evaluation and heart rate assessment using supine, standing, and exercise electrocardiography were performed at the beginning and end of each phase of the study. Ivabradine use resulted in the following outcomes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Improvement in symptoms in all patients, with 14 patients (67 percent) reporting elimination of &gt;70 percent of symptoms and 9 patients (43 percent) reporting complete resolution of symptoms while on <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant reductions in resting heart rate (from 88 to 76 beats per minute), standing heart rate (from 108 to 92 beats per minute), and heart rate during effort (176 to 158 beats per minute).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant increases in exercise time (7.2 to 8.9 minutes).</p><p></p><p>The long-term safety and efficacy of <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> is unknown. In early studies, it was shown to increase the risk for atrial fibrillation and development of phosphenes (enhanced visual brightness). Patients who develop atrial fibrillation should stop the medication. Continued use of ivabradine in the presence of phosphenes is reasonable [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/5255.html" rel="external">"Approach to the patient with visual hallucinations"</a>.)</p><p class="headingAnchor" id="H2294351"><span class="h3">Catheter ablation</span><span class="headingEndMark"> — </span>For patients with persistent symptomatic inappropriate sinus tachycardia despite optimal pharmacologic therapy, radiofrequency catheter ablation can be attempted, although ablation is performed very rarely and only after all other therapeutic options have been exhausted. The results of catheter ablation of the sinus node have been mixed. The goal is to modify the sinus node without ablating it completely to avoid the need for permanent pacemaker implantation. However, if the tachycardia is a reflex response related to POTS, ablation may lead to worsening symptoms; hence the importance of excluding POTS before attempting ablation of the sinus node. In fact, the 2015 consensus statement relegates catheter ablation/modification of the sinus node for inappropriate sinus tachycardia and for POTS as ineffective and probably harmful (class III) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/5100.html" rel="external">"Postural tachycardia syndrome", section on 'Management'</a>.)</p><p>Total sinus node ablation and sinus node modification have been attempted in small numbers of patients with inappropriate sinus tachycardia; both are technically difficult because the sinus node is a sizable (and largely epicardial) complex of cells lying along the lateral right atrial wall, not a tiny discrete focus [<a href="#rid40">40</a>]. Total sinus node ablation leaves the patient with a junctional rhythm, which usually necessitates permanent pacemaker implantation. Sinus node modification involves an initial ablation at the superior aspect of the sinoatrial nodal complex. Ablation then proceeds inferiorly until the resting heart rate and the heart rate in response to <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> infusion decrease markedly. In patients who do not respond adequately to medical therapy or endocardial ablation, an alternative approach utilizing epicardial (via the pericardial space) ablation has been described [<a href="#rid41">41,42</a>].</p><p>Although studies are limited, both in number and in duration of follow-up, ablation for inappropriate sinus tachycardia may be modestly effective in highly selected patients with expert electrophysiologists performing the procedure.</p><p class="bulletIndent1"><span class="glyph">●</span>A 2017 systematic review of the literature identified 153 patients (mean age 35 years, 91 percent female, mean heart rate 105 beats per minute by 24-hour ambulatory recording) who underwent catheter ablation after failing to adequately respond to maximal medical therapy (mean 3.5 drugs) for inappropriate sinus tachycardia [<a href="#rid40">40</a>]. Acute procedural success (not uniformly defined) was reported in 89 percent of patients, with 86 percent of patients having a successful outcome at mean follow-up of 28 months, although 20 percent of patients reported recurrent symptoms. Severe procedure complications (eg, pericardial tamponade, superior vena cava syndrome, phrenic nerve paralysis) occurred in 13 patients (9 percent), and 15 patients (10 percent) required permanent pacemaker implantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective registry of patients undergoing catheter ablation, 40 patients underwent ablation for inappropriate sinus tachycardia; acute success was achieved in 71.4 percent, but 10 percent had recurrent symptoms [<a href="#rid43">43</a>]. Other data suggest a much higher overall recurrence rate between 27 and 45 percent, in addition to the risks of right phrenic nerve injury, the future need for a pacemaker, and the risk of superior vena cava syndrome as a result of occlusion/thrombosis [<a href="#rid13">13</a>].</p><p></p><p>Sinus node ablation, however, is not effective in patients with inappropriate sinus tachycardia who have features of POTS; although the sinus rate is effectively slowed, there is no significant improvement in clinical symptoms [<a href="#rid44">44</a>]. In fact, ablation of the sinus node in POTS could lead to significant exacerbation of symptoms [<a href="#rid12">12</a>]. Given the young age of patients with inappropriate sinus tachycardia, the potential need for a pacemaker, the possible complications of the procedure (eg, phrenic nerve paralysis, superior vena cava syndrome), mixed results, and high recurrence rates, professional society guidelines do not support <strong>routine</strong> treatment with catheter ablation or modification of the sinus node for inappropriate sinus tachycardia, although it may be useful in very specific patients [<a href="#rid7">7,13,28</a>].</p><p class="headingAnchor" id="H469252622"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H23403062"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16998.html" rel="external">"Patient education: Tachycardia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10700258"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Sinus tachycardia is a rhythm in which the rate of impulses arising from the sinoatrial (SA) node is elevated. The normal heart rate has been considered historically to range from 60 to 100 beats per minute, with sinus tachycardia being defined as a sinus rhythm with a rate exceeding 100 beats per minute. However, the "normal" heart rate varies in part with age as well as level of fitness and underlying medical comorbidities  (<a class="graphic graphic_table graphicRef77746" href="/d/graphic/77746.html" rel="external">table 1</a>). (See <a class="local">'Definition and ECG features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes and syndromes</strong> – The most common cause of sinus tachycardia is a physiologic response to exercise and other conditions with catecholamine release, such as fever, volume depletion, hypoxia, pain, and anxiety. Other clinical syndromes associated with sinus tachycardia include autonomic dysregulation (eg, postural orthostatic tachycardia syndrome [POTS]) and inappropriate sinus tachycardia (cause unknown). (See <a class="local">'Etiology and clinical syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – In the vast majority of patients, physiologic sinus tachycardia itself does not directly cause symptoms, although a patient with a greater awareness of his or her heartbeat may report palpitations (manifest as the sensation of a rapid heartbeat). However, as with any tachycardia, sinus tachycardia can indirectly lead to other symptoms due to the impact of the tachycardia in the presence of underlying heart disease. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">In contrast, patients with POTS or inappropriate sinus tachycardia are generally symptomatic. (See <a class="local">'Postural orthostatic tachycardia syndrome'</a> above and <a class="local">'Inappropriate sinus tachycardia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Sinus tachycardia is generally confirmed by ECG after a rapid pulse is identified on physical examination, with the diagnosis usually being easy to establish from the surface ECG. Since the tachycardia arises from the SA node, the P waves should have a normal or near-normal appearance on ECG and should occur in a regular fashion  (<a class="graphic graphic_waveform graphicRef78938" href="/d/graphic/78938.html" rel="external">waveform 2</a>). (See <a class="local">'Confirm sinus tachycardia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For physiologic sinus tachycardia</strong> – In most settings, sinus tachycardia will improve or resolve following treatment directed at the underlying etiology. Patients with sinus tachycardia who have hypotension or signs of shock related to suspected volume depletion, signs of sepsis, or acute clinical deterioration related to another suspected medical condition (eg, hypoxia, myocardial ischemia, heart failure, etc) require admission for evaluation and treatment. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For acute coronary syndrome</strong> – Because persistent tachycardia in a patient with acute coronary syndrome can result in larger infarcts and a more marked impairment in left ventricular function, treatment of sinus tachycardia with beta blockers is appropriate in most patients. (See <a class="local">'Management in patients with acute coronary syndrome'</a> above and  <a class="medical medical_review" href="/d/html/96.html" rel="external">"Acute myocardial infarction: Role of beta blocker therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For inappropriate sinus tachycardia</strong> – Treatment of symptomatic inappropriate sinus tachycardia is challenging, often with suboptimal results. Before embarking on treatment, exclusion of secondary causes of sinus tachycardia is imperative.</p><p></p><p class="bulletIndent2">For patients with symptomatic inappropriate sinus tachycardia, we suggest a trial of beta blockade as the initial medical therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically start long-acting <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> 25 to 50 mg daily, with upward titration for adequate heart rate and symptom control. Results are often disappointing. (See <a class="local">'Beta blockers'</a> above.)</p><p></p><p class="bulletIndent2">For patients with persistently symptomatic inappropriate sinus tachycardia, we suggest using <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> (5 mg to 7.5 mg twice daily) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If symptomatic sinus tachycardia persists or the response is suboptimal, we will then add a beta blocker. Ivabradine is not available in all countries and its use for inappropriate sinus tachycardia would be considered an off-label use in the United States. (See <a class="local">'Ivabradine'</a> above.)</p><p></p><p class="bulletIndent2">For patients with persistent symptomatic inappropriate sinus tachycardia despite optimal pharmacologic therapy, radiofrequency catheter ablation may be attempted. Postural orthostatic tachycardia syndrome must be excluded first, since ablation may worsen symptoms in these patients. (See <a class="local">'Catheter ablation'</a> above.)</p><p></p><p class="headingAnchor" id="H817007758"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Leonard Ganz, MD and Brian Olshansky, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yusuf S, Camm AJ. The sinus tachycardias. Nat Clin Pract Cardiovasc Med 2005; 2:44.</a></li><li><a class="nounderline abstract_t">Palatini P. Heart rate as a cardiovascular risk factor: do women differ from men? Ann Med 2001; 33:213.</a></li><li><a class="nounderline abstract_t">Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50:823.</a></li><li><a class="nounderline abstract_t">Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 1980; 44:304.</a></li><li><a class="nounderline abstract_t">Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.</a></li><li><a class="nounderline abstract_t">Bjerregaard P. Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age. Eur Heart J 1983; 4:44.</a></li><li><a class="nounderline abstract_t">Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015; 12:e41.</a></li><li><a class="nounderline abstract_t">Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 2009; 20:352.</a></li><li><a class="nounderline abstract_t">Bauernfeind RA, Amat-Y-Leon F, Dhingra RC, et al. Chronic nonparoxysmal sinus tachycardia in otherwise healthy persons. Ann Intern Med 1979; 91:702.</a></li><li><a class="nounderline abstract_t">Morillo CA, Klein GJ, Thakur RK, et al. Mechanism of 'inappropriate' sinus tachycardia. Role of sympathovagal balance. Circulation 1994; 90:873.</a></li><li><a class="nounderline abstract_t">Krahn AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol 1995; 6:1124.</a></li><li><a class="nounderline abstract_t">Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. J Am Coll Cardiol 2013; 61:793.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016; 133:e506.</a></li><li><a class="nounderline abstract_t">Lee RJ, Shinbane JS. Inappropriate sinus tachycardia. Diagnosis and treatment. Cardiol Clin 1997; 15:599.</a></li><li><a class="nounderline abstract_t">Shabtaie SA, Witt CM, Asirvatham SJ. Natural history and clinical outcomes of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 2020; 31:137.</a></li><li><a class="nounderline abstract_t">Rubenstein JC, Freher M, Kadish A, Goldberger JJ. Diurnal heart rate patterns in inappropriate sinus tachycardia. Pacing Clin Electrophysiol 2010; 33:911.</a></li><li><a class="nounderline abstract_t">Olshansky B. What's So Inappropriate About Sinus Tachycardia? J Cardiovasc Electrophysiol 2008; 19:977.</a></li><li><a class="nounderline abstract_t">Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.</a></li><li><a class="nounderline abstract_t">Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for "inappropriate" sinus tachycardia. Circulation 1995; 92:2919.</a></li><li><a class="nounderline abstract_t">Romeo E, Grimaldi N, Sarubbi B, et al. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine. Pediatr Cardiol 2011; 32:842.</a></li><li><a class="nounderline abstract_t">Winum PF, Cayla G, Rubini M, et al. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. Pacing Clin Electrophysiol 2009; 32:942.</a></li><li><a class="nounderline abstract_t">Cossú SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis 1998; 41:51.</a></li><li><a class="nounderline abstract_t">DeSanctis RW, Block P, Hutter AM Jr. Tachyarrhythmias in myocardial infarction. Circulation 1972; 45:681.</a></li><li><a class="nounderline abstract_t">Crimm A, Severance HW Jr, Coffey K, et al. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984; 76:983.</a></li><li><a class="nounderline abstract_t">Severance HW Jr, Morris KG, Wagner GS. Criteria for early discharge after acute myocardial infarction: validation in a community hospital. Arch Intern Med 1982; 142:39.</a></li><li><a class="nounderline abstract_t">McNeer JF, Wallace AG, Wagner GS, et al. The course of acute myocardial infarction. Feasibility of early discharge of the uncomplicated patient. Circulation 1975; 51:410.</a></li><li><a class="nounderline abstract_t">Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">Femenía F, Baranchuk A, Morillo CA. Inappropriate sinus tachycardia: current therapeutic options. Cardiol Rev 2012; 20:8.</a></li><li><a class="nounderline abstract_t">DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006; 53:399.</a></li><li><a class="nounderline abstract_t">DiFrancesco D, Noble D. The funny current has a major pacemaking role in the sinus node. Heart Rhythm 2012; 9:299.</a></li><li><a class="nounderline abstract_t">Koruth JS, Lala A, Pinney S, et al. The Clinical Use of Ivabradine. J Am Coll Cardiol 2017; 70:1777.</a></li><li><a class="nounderline abstract_t">DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64:1757.</a></li><li><a class="nounderline abstract_t">Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol 2011; 107:805.</a></li><li><a class="nounderline abstract_t">Calò L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010; 7:1318.</a></li><li><a class="nounderline abstract_t">Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60:1323.</a></li><li><a class="nounderline abstract_t">Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace 2013; 15:116.</a></li><li><a class="nounderline abstract_t">Benezet-Mazuecos J, Rubio JM, Farré J, et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol 2013; 36:830.</a></li><li><a class="nounderline abstract_t">Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm 2018; 15:240.</a></li><li><a class="nounderline abstract_t">Rodríguez-Mañero M, Kreidieh B, Al Rifai M, et al. Ablation of Inappropriate Sinus Tachycardia: A Systematic Review of the Literature. JACC Clin Electrophysiol 2017; 3:253.</a></li><li><a class="nounderline abstract_t">Schweikert RA, Saliba WI, Tomassoni G, et al. Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations. Circulation 2003; 108:1329.</a></li><li><a class="nounderline abstract_t">Koplan BA, Parkash R, Couper G, Stevenson WG. Combined epicardial-endocardial approach to ablation of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol 2004; 15:237.</a></li><li><a class="nounderline abstract_t">Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol 2000; 23:1020.</a></li><li><a class="nounderline abstract_t">Shen WK, Low PA, Jahangir A, et al. Is sinus node modification appropriate for inappropriate sinus tachycardia with features of postural orthostatic tachycardia syndrome? Pacing Clin Electrophysiol 2001; 24:217.</a></li></ol></div><div id="topicVersionRevision">Topic 1074 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16265342" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The sinus tachycardias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11405541" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heart rate as a cardiovascular risk factor: do women differ from men?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17719466" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Resting heart rate in cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7426187" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/65912" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339245" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25980576" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207771" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Postural tachycardia syndrome (POTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/496102" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic nonparoxysmal sinus tachycardia in otherwise healthy persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913886" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mechanism of 'inappropriate' sinus tachycardia. Role of sympathovagal balance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8720214" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inappropriate sinus tachycardia: evaluation and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23265330" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Inappropriate sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26399663" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403163" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inappropriate sinus tachycardia. Diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31749258" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Natural history and clinical outcomes of inappropriate sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20353418" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Diurnal heart rate patterns in inappropriate sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462330" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : What's So Inappropriate About Sinus Tachycardia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051297" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Electrophysiologic effects of adenosine in patients with supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586260" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radiofrequency catheter modification of the sinus node for "inappropriate" sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21479666" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572874" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9717859" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4551930" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tachyarrhythmias in myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6731469" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7053735" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Criteria for early discharge after acute myocardial infarction: validation in a community hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1139753" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The course of acute myocardial infarction. Feasibility of early discharge of the uncomplicated patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588407" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22143280" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inappropriate sinus tachycardia: current therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638640" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Funny channels in the control of cardiac rhythm and mode of action of selective blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21925134" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The funny current has a major pacemaking role in the sinus node.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958335" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Clinical Use of Ivabradine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301560" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21247517" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20621618" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22981555" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22772053" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23510001" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017929" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759520" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ablation of Inappropriate Sinus Tachycardia: A Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952851" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Percutaneous pericardial instrumentation for endo-epicardial mapping of previously failed ablations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028057" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Combined epicardial-endocardial approach to ablation of inappropriate sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10879389" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The 1998 NASPE prospective catheter ablation registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11270703" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Is sinus node modification appropriate for inappropriate sinus tachycardia with features of postural orthostatic tachycardia syndrome?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
